Business
Obagi Medical and Moxie Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™
Moxie selected as a leading aesthetic practice software and support partner for its commitment to innovation, compliance, and empowering aesthetic
About this update from Waldencast Plc
[{"type":"text","content":"Moxie selected as a leading aesthetic practice software and support partner for its commitment to innovation, compliance, and empowering aesthetic entrepreneurs\nNEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Obagi Medical, a leading innovator in physician-dispensed skincare and aesthetic solutions and part of Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”), today announced Moxie as a strategic partner in the Aesthetics Leadership with Obagi’s Hyaluronic Acid (ALOHA) Program. Moxie was selected for its expertise in providing all-in-one software, marketing, coaching, and compliance solutions that help med spa entrepreneurs launch, scale, and optimize their practices with predictable growth, profitability, and a foundation of clinical and operational excellence. Through this real-world evaluation collaboration, Moxie will facilitate a structured assessment of Obagi® saypha® MagIQ™ across its network of supported aesthetic practices. The program will leverage Moxie’s strengths in data-driven insights, operational tools, and expert coaching to generate meaningful real-world evidence on the filler’s integration into scalable aesthetic workflows. “At Moxie, we’re dedicated to empowering aesthetic practice entrepreneurs with the tools, support, and strategies needed to build thriving, compliant practices,” said Kamau Massey, CEO of Moxie. “Obagi’s ALOHA Program resonates with our focus on innovation and real-world results, allowing us to help our partners incorporate advanced injectables like saypha® MagIQ™ alongside comprehensive skincare protocols to enhance patient outcomes and business success.” The ALOHA Program evaluates both clinical performance and patient experience while equipping providers with integrated Obagi protocols to drive satisfaction, loyalty, and consistent results. Standardized data will be collected across participating Moxie-supported practices, with initial findings to be shared at upcoming Moxie events and presented at key industry conferences to demonstrate the impact of this new injectable in technology-enabled med spa environments. “The Moxie opportunity is unique and highlights Obagi’s Aesthetics for All™ ethos with a focus on supporting practices of all sizes and shapes,\" said Drew Fine, U.S. General Manager, Professional Channel. “The ALOHA partnership with Moxie combines cutting-edge softwar...